Besponsa (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) .
Complete information about Besponsa (inotuzumab ozogamicin) dosage and administration can be found here . Prior to all infusions, patients need to be pre-medicated with a corticosteroid, antipyretic, and antihistamine . The standard dosage is:
Cycle 1 (21 days):
Day 1: 0.8 mg/m2
Day 8 : 0.5 mg/m2
Day 15: 0.5 mg/m2
Cycle 1 is 3 weeks in duration but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity.
Following cycles (28 days)
for patients who have achieved CR or CRi
Day 1: 0.5 mg/m2
Day 8: 0.5 mg/m2
Day 15: 0.5 mg/m2
for patients who have not achieved CR or CRi
Day 1: 0.8 mg/m2
Day 8: 0.5 mg/m2
Day 15: 0.5 mg/m2
Besponsa (inotuzumab ozogamicin) is given as an infusion into a vein lasting for at least one hour. The infusions are given on days 1, 8 and 15 of a 3 or 4-week treatment cycle. The treatment may be interrupted or the dose may be reduced if the patient develops certain serious side effects . Patients in whom Besponsa (inotuzumab ozogamicin) works well should receive 2 or 3 cycles, after which they can have a stem cell transplant to replace their bone marrow, the only curative treatment. Patients whose treatment works well, but who are not going to receive a stem cell transplant, may receive up to a maximum of 6 cycles of treatment. In patients who do not respond to treatment, Besponsa (inotuzumab ozogamicin) should be stopped after 3 cycles . Consult your treating doctor for personalised dosing.
What isinotuzumab ozogamicin and how does it work?
Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC) used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) . The active substance in Besponsa, inotuzumab ozogamicin, is a monoclonal antibody (a type of protein) that has been linked to a small molecule — N-acetyl-gamma-calicheamicin dimethylhydrazide — a cytotoxic agent that once activated provokes the death of cancer cells. The monoclonal antibody has been designed to recognise and attach to CD22 on the cancerous B cells. Once attached, the medicine is taken up by the cell where calicheamicin becomes active, causing breaks in the cell’s DNA and thereby killing the cancer cell .
as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL) . The approvals were based on a randomized (1:1), open-label, international, multicenter study (INO-VATE ALL (NCT01564784)) involving a total of 326 patients. The efficacy of was established on the basis of results in the initial 218 randomized patients, which were later on confirmed with those seen in all 326 randomized patients . The results of the first 218 patients showed that after at least 2 cycles of treatment, 80.7 % (88 out of 109) of patients receiving Besponsa (inotuzumab ozogamicin) responded to treatment compared with 29 % (32 out of 109) of patients receiving other chemotherapy. Of the 88 responding patients 39 achieved a complete remission (CR) and 49 a complete remission with incomplete hematologic recovery (CRi) . Patients who responded to treatment could proceed to have a stem cell transplant .
Buyer For EU individuals, VAT is 6% on medicines + 21% on shipping
Shipping Cost Estimate per order
VAT Tax can be claimed back by non-EU citizens on exiting the EU
Send this price estimate to your email address
Please complete the form, then try sending again.
*Once you provide us with the exact shipping address, the actual price may vary. After receiving the estimate, we may contact you to offer further assistance.
The more expensive medicines are patent-protected, and their prices are set by the pharmaceutical industry. We are constantly negotiating to get you best prices. As a social enterprise we only charge small fees to cover our operational costs.
Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.
If you think that this medicine may be suitable for treating your condition, get in touch.
We'll answer any questions you might have and provide you with further information. Select the
Calculate Price tab to get a close estimate of the full cost of the medicine including delivery.
If you would like us to provide you with a precise quote we'll need to know the exact address of where you want us to send your medicine to.
2. Chat with your doctor
About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.
3. Place your order
Once you have your doctor's prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or Paypal.
As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy.
Delivery time can vary from country to country but usually takes 1 to 3 weeks.
We'll send you a tracking number and keep you up to date on the status of your order.
Rest assured that we'll guide you through the entire process.
We'll let you know exactly what regulations need to be followed and the specific documentation you'll need to import the medicine into your country so that you get your treatment as quickly as possible. Ask us a question
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.
"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."
- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.
DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision.
Terms and Conditions